A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers

NCT00231829 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

23

Enrollment

OTHER

Sponsor class

Stopped Due to reported toxicity of Celecoxib at high doses

Conditions

Uterine Cancer

Interventions

DRUG: Celecoxib

Sponsor

Mark H. Einstein

Collaborators

[object Object]